Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
Disclosed herein are crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which is a prodrug of methyl hydrogen fumarate. Crystalline form 1, Crystalline form 2, Crystalline 3, and Crystalline form 4 are disclosed.
1. A method of making a pharmaceutical composition comprising combining crystalline (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate having a purity of at least 99% by weight as measured by HPLC and a pharmaceutically acceptable vehicle;
wherein the crystalline (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is selected from crystalline form 2, crystalline form 3 and crystalline form 4;
crystalline form 2 exhibits characteristic scattering angles (2θ) at least at 8.4±0.2°, 4.2±0.2°, 16.9±0.2°, 18.3±0.2°, and 20.0±0.2° in an X-ray powder diffraction pattern measured using Cu-Kα radiation;
crystalline form 3 exhibits characteristic scattering angle (2θ) at least at 20.6±0.2°, 9.5±0.2°, 11.1±0.2°, 15.8±0.2° and 18.6±0.2° in an X-ray powder diffraction pattern measured using Cu—Kα radiation; and
crystalline form 4 exhibits characteristic scattering angle (2θ) at least at 20.4±0.2°, 8.2±0.2°, 33.2±0.2°, 26.3±0.2°, and 20.8±0.2° in an X-ray powder diffraction pattern measured using Cu—Kα radiation.
2. The method of claim 1 , wherein the crystalline form is form 2 having a DSC thermogram peak of between about 49° C. and about 51° C.
3. The method of claim 1 , wherein the crystalline form 2 further comprises characteristic scattering angles (2θ) at 26.8±0.2°, 23.5±0.2°, 29.8±0.2°, 20.7±0.2° and 24.2±0.2° in an X-ray powder diffraction pattern measured using Cu—Kα radiation.
4. The method of claim 1 , wherein the crystalline form is form 3 having a DSC thermogram peak of between about 46° C. and about 48° C.
5. The method of claim 1 , wherein the crystalline form 3 further comprises characteristic scattering angles (2θ) at 20.8±0.1°, 29.2±0.1°, 19.1±0.1°, 22.2±0.1° and 24.3±0.1° in an X-ray powder diffraction pattern measured using Cu—Kα radiation.
6. The method of claim 1 , wherein the crystalline form is form 4 having a DSC thermogram peak of between about 37° C. and about 39° C.
7. The method of claim 1 , wherein the crystalline form 4 further comprises characteristic scattering angles (2θ) at 8.3±0.2°, 26.2±0.2°, 13.2±0.2°, 16.4±0.2° and 21.8±0.2° in an X-ray powder diffraction pattern measured using Cu—Kα radiation.
8. The method of claim 1 , wherein the crystalline (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate has a purity of at least 99.5% by weight as measured by HPLC.
9. The method of claim 1 , wherein the crystalline (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate has a purity of at least 99.9% by weight as measured by HPLC.
10. The method of claim 1 , wherein the pharmaceutically acceptable vehicle is selected from the group consisting of a diluent, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable excipient, a pharmaceutically acceptable carrier and a combination thereof.
11. The method of claim 10 , wherein the pharmaceutically acceptable vehicle is selected from the group consisting of sodium citrate, dicalcium phosphate and a combination thereof.
12. The method of claim 1 , wherein the pharmaceutically acceptable vehicle is selected from the group consisting of starches, lactose, sucrose, glucose, mannitol, silicic acid, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, acacia, glycerol, agar-agar, calcium carbonate, potato starch, tapioca starch, alginic acid, certain silicates, sodium carbonate, paraffin, quaternary ammonium compounds, cetyl alcohol, glycerol monostearate, kaolin, bentonite clay, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and a combination thereof.
13. The method of claim 1 , wherein the pharmaceutical formulation is an oral dosage form.
14. A method of treating a disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising crystalline (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate having a purity of at least 99% by weight as measured by HPLC and a pharmaceutically acceptable vehicle; wherein the disease is selected form the group consisting of multiple sclerosis and psoriasis;
crystalline (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is selected from crystalline form 2, crystalline form 3 and crystalline form 4;
crystalline form 2 exhibits characteristic scattering angles (2θ) at least at 8.4±0.2°, 4.2±0.2°, 16.9±0.2°, 18.3±0.2°, and 20.0±0.2° in an X-ray powder diffraction pattern measured using Cu—Kα radiation;
crystalline form 3 exhibits characteristic scattering angle (2θ) at least at 20.6±0.2°, 9.5±0.2°, 11.1±0.2°, 15.8±0.2° and 18.6±0.2° in an X-ray powder diffraction pattern measured using Cu—Kα radiation; and
crystalline form 4 exhibits characteristic scattering angle (2θ) at least at 20.4±0.2°, 8.2±0.2°, 8.2±0.2°, 26.3±0.2°, and 20.8±0.2° in an X-ray powder diffraction pattern measured using Cu—Kα radiation.